Precocious Puberty Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major precocious puberty markets are expected to exhibit a CAGR of 6.19% during 2024-2034.
The precocious puberty market has been comprehensively analyzed in IMARC's new report titled "Precocious Puberty Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Precocious puberty is defined as the premature onset of puberty in children, characterized by the development of secondary sexual characteristics before the age of 9 in boys and 8 in girls. This ailment can be a source of emotional and physical challenges for individuals suffering from it, as their bodies begin to mature faster than their peers. The symptoms vary depending on the patient’s gender: girls may experience breast development, menstruation, and rapid growth, while boys might show enlarged testicles and penis, facial hair expansion, and a deepening voice. Additionally, other common indications include bone growth, which might also lead to shorter adult height. The diagnosis of precocious puberty involves a thorough physical examination, a review of medical and family history, and certain tests. Physicians will recommend blood workups to measure hormone levels and determine the patient’s stage of sexual development. In addition to this, numerous imaging tests are utilized to identify potential underlying causes of the disease.
The increasing prevalence of premature activation of the reproductive system, triggered by the early release of hormones like gonadotropins, which can accelerate the onset of secondary sexual characteristics, is primarily driving the precocious puberty market. In addition to this, the inflating usage of therapeutic techniques, such as cognitive behavioral therapy, that are designed to enhance coping mechanisms and promote psychological well-being is creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, including gonadotropin-releasing hormone (GnRH) analogs, since they help in suppressing the release of sex hormones and slowing down the pace of puberty in individuals suffering from the ailment, is further bolstering the market growth. Apart from this, the rising utilization of educational programs aimed at raising awareness among healthcare professionals and parents about early puberty signs and management strategies is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced diagnostic methods, particularly hormonal assays and radiographic bone age determination, to detect the exact cause of the disease and tailor specific interventions is also augmenting the market growth. Furthermore, the escalating demand for gene therapy, which works by targeting and correcting the genetic anomalies responsible for the early onset of puberty, is expected to drive the precocious puberty market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the precocious puberty market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for precocious puberty and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the precocious puberty market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the precocious puberty market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the precocious puberty market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current precocious puberty marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the precocious puberty market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the precocious puberty market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the precocious puberty market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of precocious puberty across the seven major markets?
What is the number of prevalent cases (2018-2034) of precocious puberty by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of precocious puberty by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with precocious puberty across the seven major markets?
What is the size of the precocious puberty patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of precocious puberty?
What will be the growth rate of patients across the seven major markets?
Precocious Puberty: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for precocious puberty drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the precocious puberty market?
What are the key regulatory events related to the precocious puberty market?
What is the structure of clinical trial landscape by status related to the precocious puberty market?
What is the structure of clinical trial landscape by phase related to the precocious puberty market?
What is the structure of clinical trial landscape by route of administration related to the precocious puberty market?
The precocious puberty market has been comprehensively analyzed in IMARC's new report titled "Precocious Puberty Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Precocious puberty is defined as the premature onset of puberty in children, characterized by the development of secondary sexual characteristics before the age of 9 in boys and 8 in girls. This ailment can be a source of emotional and physical challenges for individuals suffering from it, as their bodies begin to mature faster than their peers. The symptoms vary depending on the patient’s gender: girls may experience breast development, menstruation, and rapid growth, while boys might show enlarged testicles and penis, facial hair expansion, and a deepening voice. Additionally, other common indications include bone growth, which might also lead to shorter adult height. The diagnosis of precocious puberty involves a thorough physical examination, a review of medical and family history, and certain tests. Physicians will recommend blood workups to measure hormone levels and determine the patient’s stage of sexual development. In addition to this, numerous imaging tests are utilized to identify potential underlying causes of the disease.
The increasing prevalence of premature activation of the reproductive system, triggered by the early release of hormones like gonadotropins, which can accelerate the onset of secondary sexual characteristics, is primarily driving the precocious puberty market. In addition to this, the inflating usage of therapeutic techniques, such as cognitive behavioral therapy, that are designed to enhance coping mechanisms and promote psychological well-being is creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, including gonadotropin-releasing hormone (GnRH) analogs, since they help in suppressing the release of sex hormones and slowing down the pace of puberty in individuals suffering from the ailment, is further bolstering the market growth. Apart from this, the rising utilization of educational programs aimed at raising awareness among healthcare professionals and parents about early puberty signs and management strategies is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced diagnostic methods, particularly hormonal assays and radiographic bone age determination, to detect the exact cause of the disease and tailor specific interventions is also augmenting the market growth. Furthermore, the escalating demand for gene therapy, which works by targeting and correcting the genetic anomalies responsible for the early onset of puberty, is expected to drive the precocious puberty market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the precocious puberty market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for precocious puberty and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the precocious puberty market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the precocious puberty market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the precocious puberty market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current precocious puberty marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the precocious puberty market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the precocious puberty market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the precocious puberty market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of precocious puberty across the seven major markets?
What is the number of prevalent cases (2018-2034) of precocious puberty by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of precocious puberty by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with precocious puberty across the seven major markets?
What is the size of the precocious puberty patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of precocious puberty?
What will be the growth rate of patients across the seven major markets?
Precocious Puberty: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for precocious puberty drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the precocious puberty market?
What are the key regulatory events related to the precocious puberty market?
What is the structure of clinical trial landscape by status related to the precocious puberty market?
What is the structure of clinical trial landscape by phase related to the precocious puberty market?
What is the structure of clinical trial landscape by route of administration related to the precocious puberty market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PRECOCIOUS PUBERTY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PRECOCIOUS PUBERTY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PRECOCIOUS PUBERTY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PRECOCIOUS PUBERTY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PRECOCIOUS PUBERTY - UNMET NEEDS
10 PRECOCIOUS PUBERTY - KEY ENDPOINTS OF TREATMENT
11 PRECOCIOUS PUBERTY - MARKETED PRODUCTS
11.1 List of Precocious Puberty Marketed Drugs Across the Top 7 Markets
11.1.1 Lupron Depot PED (Leuprorelin depot) - AbbVie/Takeda
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Triptodur (Triptorelin) - Debiopharm
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Fensolvi (Leuprorelin) - Tolmar
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PRECOCIOUS PUBERTY - PIPELINE DRUGS
12.1 List of Precocious Puberty Pipeline Drugs Across the Top 7 Markets
12.1.1 Fulvestrant - AstraZeneca
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PRECOCIOUS PUBERTY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PRECOCIOUS PUBERTY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PRECOCIOUS PUBERTY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Precocious Puberty - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Precocious Puberty - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Precocious Puberty - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Precocious Puberty - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Precocious Puberty - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Precocious Puberty - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Precocious Puberty - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Precocious Puberty - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Precocious Puberty - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Precocious Puberty - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Precocious Puberty - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Precocious Puberty - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Precocious Puberty - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Precocious Puberty - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Precocious Puberty - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Precocious Puberty - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Precocious Puberty - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Precocious Puberty - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Precocious Puberty - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Precocious Puberty - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Precocious Puberty - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Precocious Puberty - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Precocious Puberty - Access and Reimbursement Overview
16 PRECOCIOUS PUBERTY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PRECOCIOUS PUBERTY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PRECOCIOUS PUBERTY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PRECOCIOUS PUBERTY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PRECOCIOUS PUBERTY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PRECOCIOUS PUBERTY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PRECOCIOUS PUBERTY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PRECOCIOUS PUBERTY - UNMET NEEDS
10 PRECOCIOUS PUBERTY - KEY ENDPOINTS OF TREATMENT
11 PRECOCIOUS PUBERTY - MARKETED PRODUCTS
11.1 List of Precocious Puberty Marketed Drugs Across the Top 7 Markets
11.1.1 Lupron Depot PED (Leuprorelin depot) - AbbVie/Takeda
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Triptodur (Triptorelin) - Debiopharm
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Fensolvi (Leuprorelin) - Tolmar
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PRECOCIOUS PUBERTY - PIPELINE DRUGS
12.1 List of Precocious Puberty Pipeline Drugs Across the Top 7 Markets
12.1.1 Fulvestrant - AstraZeneca
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PRECOCIOUS PUBERTY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PRECOCIOUS PUBERTY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PRECOCIOUS PUBERTY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Precocious Puberty - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Precocious Puberty - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Precocious Puberty - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Precocious Puberty - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Precocious Puberty - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Precocious Puberty - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Precocious Puberty - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Precocious Puberty - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Precocious Puberty - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Precocious Puberty - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Precocious Puberty - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Precocious Puberty - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Precocious Puberty - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Precocious Puberty - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Precocious Puberty - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Precocious Puberty - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Precocious Puberty - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Precocious Puberty - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Precocious Puberty - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Precocious Puberty - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Precocious Puberty - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Precocious Puberty - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Precocious Puberty - Access and Reimbursement Overview
16 PRECOCIOUS PUBERTY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PRECOCIOUS PUBERTY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PRECOCIOUS PUBERTY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
